Povezanost između sistemske inflamacije i metabolizma lipida u razvoju preeklampsije

  • Tamara Gojković Univerzitet u Beogradu - Farmaceutski fakultet, Katedra za medicinsku biohemiju, Beograd, Srbija
  • Daniela Ardalić Ginekološko-akušerska klinika Narodni Front, Beograd, Srbija
  • Gorica Banjac Ginekološko-akušerska klinika Narodni Front, Beograd, Srbija
  • Jelena Vekić Univerzitet u Beogradu - Farmaceutski fakultet, Katedra za medicinsku biohemiju, Beograd, Srbija
  • Aleksandra Zeljković Univerzitet u Beogradu - Farmaceutski fakultet, Katedra za medicinsku biohemiju, Beograd, Srbija
  • Jelena Munjas Univerzitet u Beogradu - Farmaceutski fakultet, Katedra za medicinsku biohemiju, Beograd, Srbija
  • Milica Miljković-Trailović Univerzitet u Beogradu - Farmaceutski fakultet, Katedra za medicinsku biohemiju, Beograd, Srbija
  • Snežana Jovičić Univerzitet u Beogradu - Farmaceutski fakultet, Katedra za medicinsku biohemiju, Beograd, Srbija
  • Marija Sarić Matutinović Univerzitet u Beogradu - Farmaceutski fakultet, Katedra za medicinsku biohemiju, Beograd, Srbija
  • Vesna Spasojević-Kalimanovska Univerzitet u Beogradu - Farmaceutski fakultet, Katedra za medicinsku biohemiju, Beograd, Srbija
  • Željko Miković Ginekološko-akušerska klinika Narodni Front, Beograd, Srbija; Univerzitet u Beogradu- Medicinski fakultet, Beograd, Srbija
  • Aleksandra Stefanović Univerzitet u Beogradu - Farmaceutski fakultet, Katedra za medicinsku biohemiju, Beograd, Srbija
DOI: https://doi.org/10.5937/arhfarm75-55585
Ključne reči: preeklampsija, visokorizična trudnoća, lipidni profil, inflamacija

Sažetak


Preeklampsija (PE) je komplikacija trudnoće koju karakterišu hipertenzija (≥ 140/90 mmHg) i proteinurija (≥ 300 mg/24 h), sa nejasnom patogenezom koja uključuje inflamaciju i dislipidemiju. Cilj ove studije bio je longitudinalno ispitivanje promena u koncentracijama parametara lipidnog statusa i inflamatornim markerima kod trudnica sa visokim rizikom za razvoj PE i onih koje su razvile PE. Od 91 žene, 20 je razvilo PE (PE grupa), a 71 je bila visokorizična (HR grupa). Obe grupe su praćene u četiri vremenske tačke: T1-prvi, T2-drugi, T3-treći trimestar, i T4-predporođaj. Kvantifikovani su lipidni parametri (trigliceridi (TG), ukupni holesterol (TC), HDL-C, LDL-C, apolipoproteini A-I i B-100) i inflamatorni markeri (visokoosetljivi C-reaktivni protein (hsCRP), rezistin, serumski amiloid A (SAA) i monocitni hemoatraktantni protein-1 (MCP-1)). Rezultati su pokazali značajno veće koncentracije TG, resistina i MCP-1 u PE grupi u odnosu na HR grupu u T1 (p < 0.05, p < 0.01, p < 0.01, respektivno). Tokom trudnoće, obe grupe su pokazale porast koncentracija TC, LDL-C, TG, SAA i MCP-1 (p < 0.001), dok su koncentracije HDL-C i resistina značajno porasle samo u HR grupi (p < 0.001). Razvoj PE je povezan sa aterogenim promenama lipidnog statusa, okarakterisanim hipertrigliceridemijom, bez promena u HDL-C koncentracijama, pri čemu povećanje SAA potencijalno smanjuje zaštitnu ulogu HDL-a.

Reference

Soma-Pillay P, Nelson-Piercy C, Tolppanen H, Mebazaa A. Physiological changes in pregnancy. Cardiovasc J Afr. 2016;2:89–94.

Suvakov S, Kattah AG, Gojkovic T, Enninga EA, Pruett J, Jayachandran M, et al. Impact of aging and cellular senescence in the pathophysiology of preeclampsia. Compr Physiol. 2023;4:5077–114.

Wild R, Feingold KR. Effect of pregnancy on lipid metabolism and lipoprotein levels. Endotext [Internet]. 2023 [cited 2024 Dec 15]. Available from: https://www.ncbi.nlm.nih.gov/

books/NBK498654/

Herrera E, Ortega-Senovilla H. Maternal lipid metabolism during normal pregnancy and its implications to fetal development. Clin Lipidol. 2010;6:899–911.

Grantz KL, Elmi A, Pugh SJ, Catov JM, Sjaarda L, Albert PS. Maternal serum lipid trajectories and association with pregnancy loss and length of gestation. Am J Perinatol. 2020;9:914–23.

Woollett LA, Catov JM, Jones HN. Roles of maternal HDL during pregnancy. Biochim Biophys Acta Mol Cell Biol Lipids. 2022;3:159–66.

Banait T, Wanjari A, Danade V, Banait S, Jain J. Role of high-sensitivity C-reactive protein (Hs-CRP) in non-communicable diseases: a review. Cureus. 2022;10:e29680.

Sack Jr GH. Serum amyloid A – a review. Mol Med. 2018;1:46.

Webb NR. High-density lipoproteins and serum amyloid A (SAA). Curr Atheroscler Rep. 2021;23:1–8.

Schuchardt M, Prüfer N, Tu Y, Herrmann J, Hu XP, Chebli S, et al. Dysfunctional high-density lipoprotein activates toll-like receptors via serum amyloid A in vascular smooth muscle cells. Sci Rep. 2019;9(1):3421.

Bardou M, Hadi T, Mace G, Pesant M, Debermont J, Barrichon M, et al. Systemic increase in human maternal circulating CD14+ CD16− MCP-1+ monocytes as a marker of labor. Am J Obstet Gynecol. 2014;1:70.e1.

Floeck A, Ferrari N, Joisten C, Puth MT, Strizek B, Dolscheid-Pommerich R, et al. Resistin in pregnancy: analysis of determinants in pairs of umbilical cord blood and maternal serum. Cytokine X. 2021;2:100052.

National Institute for Health and Clinical Excellence. Hypertension in pregnancy: the management of hypertensive disorders during pregnancy. NICE; 2010.

The American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 202: Gestational Hypertension and Preeclampsia. Obstet Gynecol. 2019;133:e1-25.

Sharma D, Shastri S, Sharma P. Intrauterine growth restriction: antenatal and postnatal aspects. Clin Med Insights Pediatr. 2016;10:67–83.

Katz ED, Ruoff BE. Commonly Used Formulas and Calculations. In: Roberts J, Hedges J, editors. Clinical Procedures in Emergency Medicine, 4th ed. Elsevier Mosby Publishing: Philadelphia, PA, USA, 2004; p. 1434.

Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499–502.

Virani SS. Non-HDL cholesterol as a metric of good quality of care: opportunities and challenges. Tex Heart Inst J. 2011;38(2):160.

English FA, Kenny LC, McCarthy FP. Risk factors and effective management of preeclampsia. Integr Blood Press Control. 2015;3:7–12.

De Kat AC, Hirst J, Woodward M, Kennedy S, Peters SA. Prediction models for preeclampsia: A systematic review. Pregnancy Hypertens. 2019;16:48–66.

Mayrink J, Souza RT, Feitosa FE, Rocha Filho EA, Leite DF, Vettorazzi J, et al. Mean arterial blood pressure: potential predictive tool for preeclampsia in a cohort of healthy nulliparous pregnant women. BMC Pregnancy Childbirth. 2019;19:1–8.

Mankuta D, Elami-Suzin M, Elhayani A, Vinker S. Lipid profile in consecutive pregnancies. Lipids Health Dis. 2010;9:1–4.

Bao W, Dar S, Zhu Y, Wu J, Rawal S, Li S, et al. Plasma concentrations of lipids during pregnancy and the risk of gestational diabetes mellitus: A longitudinal study. J Diabetes. 2018;6:487–95.

Sharami SH, Tangestani A, Faraji R, Zahiri Z, Amiri A. Role of dyslipidemia in preeclamptic overweight pregnant women. Iran J Reprod Med. 2012;2:105.

Melhem H, Kallol S, Huang X, Lüthi M, Ontsouka CE, Keogh A, et al. Placental secretion of apolipoprotein A1 and E: the anti-atherogenic impact of the placenta. Sci Rep. 2019;1:6225.

Gil-Acevedo L, Ceballos G, Torres-Ramos Y. Foetal lipoprotein oxidation and preeclampsia. Lipids Health Dis. 2022;21:51.

Diareme M, Karkalousos P, Theodoropoulos G, Strouzas S, Lazanas N. Lipid profile of healthy women during normal pregnancy. J Med Biochem. 2009;3:152–63.

Gugliucci A. Biomarkers of dysfunctional visceral fat. Adv Clin Chem. 2022;109:1–30.

Nien JK, Mazaki-Tovi S, Romero R, Kusanovic JP, Erez O, Gotsch F, et al. Resistin: a hormone which induces insulin resistance is increased in normal pregnancy. J Perinat Med. 2007;6:513–21.

Siddiqui K, George TP. Resistin role in development of gestational diabetes mellitus. Biomarkers Med. 2017;7:579–86.

Parisi F, Milazzo R, Savasi VM, Cetin I. Maternal low-grade chronic inflammation and intrauterine programming of health and disease. Int J Mol Sci. 2021;4:1732.

Bogavac MA, Ćelić DD, Perić TM. A prospective study of mid-trimester MCP-1 levels as a predictor of preterm delivery. Medicines. 2022;1:7.

Garcia MS, Mobley Y, Henson J, Davies M, Skariah A, Dambaeva S, et al. Early pregnancy immune biomarkers in peripheral blood may predict preeclampsia. J Reprod Immunol. 2018;125:25–31.

Joshi K, Acharya N, Acharya S, Joshi S. Maternal serum high-sensitivity C-reactive protein (hsCRP) as a prognostic marker of fetomaternal outcome in hypertensive disorders of pregnancy: a novel study. Cureus. 2022;4:1–9.

Dhok AJ, Daf S, Mohod K, Kumar S. Role of early second trimester high sensitivity C-reactive protein for prediction of adverse pregnancy outcome. JK Sci. 2011;3:141–4.

Ebert R, Benisch P, Krug M, Zeck S, Meißner-Weigl J, Steinert A, et al. Acute phase serum amyloid A induces proinflammatory cytokines and mineralization via toll-like receptor 4 in mesenchymal stem cells. Stem Cell Res. 2015;1:231–9.

Lin YK, Zhu P, Wang WS, Sun K. Serum amyloid A, a host-derived DAMP in pregnancy? Front Immunol. 2022;13:978929.

Objavljeno
2025/02/23
Broj časopisa
Vol. 75 Br. Notebook 1 (2025): Arhiv za farmaciju
Rubrika
Originalni naučni rad
Autori koji objavljuju u ovom časopisu pristaju na sledeće uslove:

  1. Autori zadržavaju autorska prava i pružaju časopisu pravo prvog objavljivanja rada i licenciraju ga "Creative Commons Attribution licencom" koja omogućava drugima da dele rad, uz uslov navođenja autorstva i izvornog objavljivanja u ovom časopisu.

  2. Autori mogu izraditi zasebne, ugovorne aranžmane za neekskluzivnu distribuciju članka objavljenog u časopisu (npr. postavljanje u institucionalni repozitorijum ili objavljivanje u knjizi), uz navođenje da je članak izvorno objavljen u ovom časopisu.

  3. Autorima je dozvoljeno i podstiču se da postave objavljeni članak onlajn (npr. u institucionalni repozitorijum ili na svoju internet stranicu) pre ili tokom postupka prijave rukopisa, s obzirom da takav postupak može voditi produktivnoj razmeni ideja i ranijoj i većoj citiranosti objavljenog članka (Vidi Efekti otvorenog pristupa).